Diabetes Mellitus Clinical Trial
Official title:
Ultrasound-Guided Infraclavicular Brachial Plexus Block Properties in Diabetic and Non-diabetic Patients: A Prospective Observational Study
NCT number | NCT03486535 |
Other study ID # | 2018/203 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | February 20, 2018 |
Est. completion date | January 31, 2019 |
Verified date | March 2018 |
Source | Istanbul University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background and objectives: The investigators are performing this study to explore whether the
presence of diabetes mellitus (DM) will affect the outcomes of infraclavicular brachial
plexus blocks (ICBs) in patients undergoing elbow, forearm and hand surgery.
The primary hypothesis is that the sensory block duration will be delaying in diabetic
patients.
Methods: Ethics committee approval has been obtained and after written informed consents, 60
patients are planning to be enrolled to the study. Diabetic patients will be included in
Group DM and non-diabetics are included in Group NODM. All patients will receive
ultrasound-guided ICBs with the mixture of 15 mL lidocaine 2% and 15 mL bupivacaine 0.5%. Our
primary outcome is sensory block duration, and secondary outcomes are sensory and motor block
onset times, motor block duration, time-to-first-pain (numeric rating scale (NRS)
≥4), postoperative NRS scores and rescue analgesic consumption (NRS) ≥4) through the
postoperative first 2 days. All outcomes will be assessed by blind investigators.
Status | Completed |
Enrollment | 60 |
Est. completion date | January 31, 2019 |
Est. primary completion date | January 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 80 Years |
Eligibility |
Inclusion Criteria: Patients scheduled for arm, elbow, forearm, and hand surgery American Society of Anesthesiologists (ASA) physical status I-IV No regional anesthesia contraindication Exclusion Criteria: Type 1 DM, Type 2 DM patients with only 'diet-controlled' therapy Difficulty with understanding the block and follow-up instructions Significant neurologic disorders Psychiatric or cognitive disorders History of substance abuse Acute and/or chronic opioid use Local anaesthetic hypersensitivity or allergy |
Country | Name | City | State |
---|---|---|---|
Turkey | Istanbul University, Medical Faculty of Istanbul | Istanbul | |
Turkey | Metin Sabanci Baltalimani Kemik Hastaliklari Training and Research Hospital | Istanbul |
Lead Sponsor | Collaborator |
---|---|
Istanbul University |
Turkey,
Cuvillon P, Reubrecht V, Zoric L, Lemoine L, Belin M, Ducombs O, Birenbaum A, Riou B, Langeron O. Comparison of subgluteal sciatic nerve block duration in type 2 diabetic and non-diabetic patients. Br J Anaesth. 2013 May;110(5):823-30. doi: 10.1093/bja/ae — View Citation
Salviz EA, Onbasi S, Ozonur A, Orhan-Sungur M, Berkoz O, Tugrul KM. Comparison of Ultrasound-Guided Axillary Brachial Plexus Block Properties in Diabetic and Nondiabetic Patients: A Prospective Observational Study. J Hand Surg Am. 2017 Mar;42(3):190-197. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensory block duration | Time interval between a successful block (0: full sensation, 1: less sensation, and 2: no sensation) (=7/8) and the complete restoration of all the senses controlled by the radial, ulnar, median and musculocutaneous nerves (0/8) | 0-24 hours | |
Secondary | Sensory block onset time | Physical examination with pin-prick test until the block onset (0: full sensation, 1: less sensation, and 2: no sensation) (=7/8) | 0-30 minutes | |
Secondary | Motor block onset time | Physical examination with modified Bromage scale until the block onset (0: normal motor function; 1: partial motor block, able to flex the elbow and move the fingers but unable to raise the extended arm; 2: almost complete motor block, unable to flex the elbow but able to move the fingers; and 3: complete motor block, unable to move the arm, elbow, or fingers) (=9/12) | 0-30 minutes | |
Secondary | Motor block duration | Time interval between a successful block (0: normal motor function; 1: partial motor block, able to flex the elbow and move the fingers but unable to raise the extended arm; 2: almost complete motor block, unable to flex the elbow but able to move the fingers; and 3: complete motor block, unable to move the arm, elbow, or fingers) (=9/12) and the complete restoration of all motor responses controlled by the radial, ulnar, median and musculocutaneous nerves (0/12). | 0-24 hours | |
Secondary | Time-to-first pain | Postoperative first pain (Numeric rating scale (NRS) =4) (0: no pain, 10: worst pain imaginable) | 0-48 hours | |
Secondary | Pain (NRS) scores | Numeric rating scale (Numeric rating scale (NRS) =4) pain scores (0: no pain, 10: worst pain imaginable) | 0-48 hours | |
Secondary | Rescue analgesic consumption | Used postoperatively if (Numeric rating scale (NRS) =4) (0: no pain, 10: worst pain imaginable) | 0-48 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |